Posters

The cross-linking treatment of pellucid marginal degeneration of cornea

Poster Details

First Author: M. Bikbov RUSSIAN FEDERATION

Co Author(s):    M. Bikbov   V. Surkova   G. Bikbova   N. Zaynullina   A. Khalimov        

Abstract Details

Purpose:

To study the clinical efficacy of crosslinking with the progressive course of pellucid marginal degeneration of the cornea.

Setting:

Ufa Eye Research Institute, Ufa, Russia

Methods:

The study conducted on 12 patients (16 eyes) with pellucid marginal corneal degeneration. Corneal thickness at thinnest point averaged 468±36 microns, the average refractive power of the cornea - Kave - 47.9±1.3D, corneal astigmatism - 5.8±1.3D, UCVA - 0.08±0.03, BCVA - 0.4±0.15. Crosslinking was performed by the standard method, according to the Dresden protocol. All patients underwent conventional ophthalmic and additional research methods, including corneal topography (OPD-scan, Nidek), OCT anterior eye segment (Carl Zeiss), corneal confocal microscopy (Heidelberg Engeneering, Germany). Follow-up period of 12 months.

Results:

1 month after decrease of UCVA and BCVA on average 0.02±0.01 and 0.1±0.08, increasing of Kave up to 48.4±4.5D and corneal thickness to 480±130 mc (r≥0.06), astigmatism reduced to 5.6 ±2.5 D. After 6 months improvement of BCVA by 0.58 ± 0.13. Corneal thickness at the center was on average 442±89 microns, Kave - 44.7±1.6D, corneal astigmatism - 4.2±1.5D (p<0.05). After 1 year of treatment UCVA - 0.1±0.08 (p≤0.07). VA was improved in 13 cases, has not changed in two and decreased in one case, averaging 0.54±0.2. Kave - 45.7±4.9D, corneal astigmatism decreased to 4.6±0.9D.

Conclusions:

Implementation of standard corneal collagen crosslinking treatment for pellucid marginal corneal degeneration contributes to the stabilization of the process during the first year observation. To improve the refractive outcomes recommended its use in combination with intrastromal keratoplasty.

Financial Disclosure:

NONE